Jeff Brown’s Top 5 Biotech IPOs of 2021
“Timed Stocks” are what Silicon Valley legend Jeff Brown calls stocks that, thanks to the federal government, have a preset countdown “timer” attached to their share price…

And the exact second the timer hits zero, the stock can skyrocket (up to a rare 23,200% in a day).
It’s $199 worth of research… but you can get it for FREE.

KALV Insider Trading (KalVista Pharmaceuticals)

Insider Ownership Percentage: 18.00%
Insider Buying (Last 12 Months): $1,994,426.64
Insider Selling (Last 12 Months): $2,378,053.03

KalVista Pharmaceuticals Insider Trading History Chart

KalVista Pharmaceuticals Share Price & Price History

$30.53
▼ -0.35 (-1.13%)
As of 03/8/2021 04:59 PM ET
Days: 30 | 90 | 365
Free 2021 Gold IRA Report:
Learn from the experts how to protect & preserve your wealth from the looming financial crisis!
Detail here.
pixel

KalVista Pharmaceuticals Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/23/2021Benjamin L PalleikoCFOSell29,642$33.59$995,674.7894,642  
2/23/2021Christopher YeaInsiderSell15,000$33.59$503,850.0062,169  
2/23/2021Thomas Andrew CrockettCEOSell10,000$33.55$335,500.00  
10/30/2020Albert ChaDirectorBuy115,686$17.24$1,994,426.64  
10/29/2020Christopher YeaInsiderSell5,000$17.48$87,400.0062,969  
10/20/2020Christopher YeaInsiderSell7,942$17.49$138,905.5876,315  
10/20/2020Thomas Andrew CrockettCEOSell15,994$17.49$279,735.06222,741  
10/16/2020Christopher YeaInsiderSell914$17.00$15,538.0081,955  
10/16/2020Thomas Andrew CrockettCEOSell1,261$17.01$21,449.61236,959  
12/16/2019Christopher YeaInsiderSell3,010$17.05$51,320.5083,168  
12/16/2019Thomas Andrew CrockettCEOSell5,400$17.06$92,124.00248,320  
12/13/2019Christopher YeaInsiderSell1,500$17.05$25,575.0083,168  
12/12/2019Thomas Andrew CrockettCEOSell100$17.00$1,700.00248,320  
9/26/2019Daniel B SolandDirectorBuy2,038$11.90$24,252.202,038  
7/29/2019Albert ChaDirectorBuy56,367$16.99$957,675.33  
7/26/2019Albert ChaDirectorBuy26,500$16.83$445,995.00  
7/23/2019Edward P FeenerInsiderSell3,300$18.62$61,446.0098,634  
7/19/2019Albert ChaDirectorBuy61,280$17.79$1,090,171.20  
7/17/2019Albert ChaDirectorBuy1,280$16.96$21,708.80  
7/15/2019Thomas Andrew CrockettCEOSell10,000$17.04$170,400.00248,510  
4/22/2019Benjamin L PalleikoCFOSell3,073$25.70$78,976.1033,573  
4/22/2019Christopher YeaInsiderSell7,355$26.04$191,524.2090,324  
4/18/2019Benjamin L PalleikoCFOSell1,073$25.51$27,372.2333,573  
4/17/2019Edward P FeenerInsiderSell4,000$24.92$99,680.00100,950  
4/15/2019Thomas Andrew CrockettCEOSell10,000$24.80$248,000.00258,810  
4/10/2019Life Sciences Fund Iv (Gp) SvMajor ShareholderSell50,000$29.20$1,460,000.00  
4/8/2019Svlsf Iv, LlcMajor ShareholderSell22,800$29.49$672,372.00  
4/5/2019Andreas MaetzelInsiderSell5,000$30.00$150,000.005,000  
4/2/2019Life Sciences Fund Iv (Gp) SvMajor ShareholderSell97,074$28.03$2,720,984.22  
3/28/2019Life Sciences Fund Iv (Gp) SvMajor ShareholderSell124,675$28.84$3,595,627.00  
3/26/2019Svlsf Iv, LlcMajor ShareholderSell30,093$29.70$893,762.10  
3/18/2019Venrock Healthcare Capital ParMajor ShareholderSell500,000$28.75$14,375,000.00  
3/14/2019Thomas Andrew CrockettCEOSell3,000$30.16$90,480.00268,510  
3/4/2019Svlsf Iv, LlcMajor ShareholderSell43,378$22.91$993,789.98  
2/21/2019Life Sciences Fund Iv (Gp) SvMajor ShareholderSell214,198$20.55$4,401,768.90  
1/25/2019Christopher YeaInsiderSell5,453$17.06$93,028.1888,422  
1/23/2019Christopher YeaInsiderSell1,902$17.01$32,353.0284,271  
1/16/2019Edward P FeenerInsiderSell4,000$19.55$78,200.00106,334  
1/14/2019Thomas Andrew CrockettCEOSell10,000$19.33$193,300.00272,411  
1/7/2019Life Sciences Fund Iv (Gp) SvMajor ShareholderSell4,299$20.25$87,054.75  
1/2/2019Svlsf Iv, LlcMajor ShareholderSell200$20.00$4,000.00  
12/31/2018Svlsf Iv, LlcMajor ShareholderSell25,418$20.00$508,360.00  
12/28/2018Svlsf Iv, LlcMajor ShareholderSell3,734$20.03$74,792.02  
12/19/2018Life Sciences Fund Iv (Gp) SvMajor ShareholderSell2,136$20.02$42,762.72  
9/10/2018Albert ChaDirectorBuy1,058,824$17.00$18,000,008.00  
See Full Table

SEC Filings (Institutional Ownership Changes) for KalVista Pharmaceuticals (NASDAQ:KALV)

90.19% of KalVista Pharmaceuticals stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

KalVista Pharmaceuticals Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in Company
3/8/2021Dimensional Fund Advisors LP206,517$3.92M0.0%+5.3%1.151%
2/25/2021Dimensional Fund Advisors LP206,517$3.92M0.0%+5.3%1.151%
2/19/2021JPMorgan Chase & Co.35,573$0.68M0.0%+52.8%0.198%
2/19/2021Albion Financial Group UT1,762$33K0.0%N/A0.010%
2/18/2021Ghost Tree Capital LLC200,000$3.80M0.8%-42.9%1.115%
2/17/2021Samsara BioCapital LLC67,270$1.28M0.1%-20.0%0.375%
2/16/2021Nuveen Asset Management LLC83,838$1.59M0.0%-24.3%0.467%
2/16/2021Janus Henderson Group PLC160,511$3.05M0.0%-5.0%0.895%
2/16/2021Charles Schwab Investment Management Inc.33,587$0.64M0.0%+8.4%0.187%
2/13/2021American International Group Inc.8,486$0.16M0.0%+4.1%0.047%
2/11/2021Northern Trust Corp229,244$4.35M0.0%-4.0%1.278%
2/11/2021Barclays PLC13,680$0.26M0.0%-6.7%0.076%
2/11/2021Citigroup Inc.3,576$68K0.0%+289.5%0.020%
2/11/2021Asymmetry Capital Management L.P.46,910$0.89M0.4%N/A0.261%
2/10/2021Rhumbline Advisers18,989$0.36M0.0%+20.5%0.106%
2/10/2021Renaissance Technologies LLC49,428$0.94M0.0%N/A0.275%
2/9/2021Wells Fargo & Company MN38,177$0.73M0.0%-23.3%0.213%
2/9/2021Bank of New York Mellon Corp45,329$0.86M0.0%+7.7%0.253%
2/8/2021Alliancebernstein L.P.18,800$0.36M0.0%-4.6%0.105%
2/8/2021Russell Investments Group Ltd.22,486$0.43M0.0%-81.4%0.125%
2/5/2021Koshinski Asset Management Inc.29,144$0.31M0.0%N/A0.162%
2/5/2021BlackRock Inc.1,113,380$21.14M0.0%+21.7%6.205%
2/5/2021SG Americas Securities LLC5,476$0.10M0.0%N/A0.031%
2/4/2021GSA Capital Partners LLP22,664$0.43M0.1%-11.0%0.126%
2/4/2021State of Wisconsin Investment Board20,300$0.39M0.0%N/A0.113%
2/2/2021Koshinski Asset Management Inc.29,144$0.31M0.1%N/A0.162%
11/17/2020California State Teachers Retirement System20,406$0.26M0.0%+4.4%0.114%
11/17/2020Logos Global Management LP300,000$3.78M0.5%-46.7%1.675%
11/16/2020Samsara BioCapital LLC84,087$1.06M0.3%-50.0%0.470%
11/16/2020Boothbay Fund Management LLC131,822$1.66M0.1%+5.5%0.736%
11/13/2020Morgan Stanley5,052$63K0.0%-18.2%0.028%
11/13/2020Charles Schwab Investment Management Inc.30,990$0.39M0.0%-4.4%0.173%
11/12/2020JPMorgan Chase & Co.23,280$0.29M0.0%-25.2%0.130%
11/10/2020State Street Corp260,565$3.28M0.0%+3.5%1.455%
11/6/2020BlackRock Inc.914,734$11.52M0.0%-1.0%5.108%
11/6/2020GSA Capital Partners LLP25,466$0.32M0.1%N/A0.142%
11/5/2020California Public Employees Retirement System30,800$0.39M0.0%+11.6%0.172%
11/5/2020Wells Fargo & Company MN49,781$0.63M0.0%+4.4%0.278%
11/4/2020Alps Advisors Inc.22,822$0.29M0.0%-6.3%0.127%
10/30/2020BNP Paribas Arbitrage SA3,538$45K0.0%+208.2%0.020%
10/22/2020NEXT Financial Group Inc4,527$57K0.0%N/A0.025%
8/25/2020Nuveen Asset Management LLC110,535$1.34M0.0%+95.0%0.619%
8/20/2020Charles Schwab Investment Management Inc.32,421$0.39M0.0%+8.7%0.182%
8/17/2020Jacobs Levy Equity Management Inc.16,128$0.20M0.0%N/A0.090%
8/14/2020Opaleye Management Inc.461,500$5.58M1.1%+105.1%2.586%
8/14/2020PDT Partners LLC16,325$0.20M0.0%-15.4%0.091%
8/14/2020Bank of America Corp DE19,037$0.23M0.0%-4.9%0.107%
8/14/2020Logos Global Management LP562,900$6.81M1.4%N/A3.154%
8/14/2020Ikarian Capital LLC1,113,395$13.47M1.1%+17.6%6.239%
8/13/2020FMR LLC1,763,856$21.34M0.0%-1.5%9.882%
8/12/2020Algert Global LLC11,129$0.14M0.0%-40.9%0.062%
8/12/2020Goldman Sachs Group Inc.36,781$0.45M0.0%N/A0.206%
8/12/2020Bank of New York Mellon Corp42,180$0.51M0.0%+20.3%0.236%
8/12/2020California Public Employees Retirement System27,600$0.33M0.0%+111.5%0.155%
8/7/2020Trexquant Investment LP13,169$0.16M0.0%N/A0.074%
8/5/2020Alps Advisors Inc.24,350$0.30M0.0%-24.8%0.136%
8/4/2020Quantitative Systematic Strategies LLC10,910$0.13M0.0%N/A0.061%
7/31/2020UBS Group AG4,315$52K0.0%-42.6%0.024%
7/24/2020Dupont Capital Management Corp14,353$0.17M0.0%N/A0.080%
7/14/2020International Biotechnology Trust PLC177,433$2.25M0.7%-22.0%0.994%
6/19/2020State Street Corp245,001$1.87M0.0%+5.6%1.373%
5/18/2020Vivo Capital LLC1,476,796$11.30M1.0%N/A8.273%
5/18/2020International Biotechnology Trust PLC227,433$1.73M0.8%-18.0%1.274%
5/15/2020Orbimed Advisors LLC420,641$3.22M0.1%+162.0%2.357%
5/15/2020Squarepoint Ops LLC75,910$0.58M0.0%-38.3%0.425%
5/15/2020Invesco Ltd.10,884$83K0.0%N/A0.061%
5/15/2020DAFNA Capital Management LLC234,952$1.80M0.7%+850.3%1.317%
5/15/2020Ghost Tree Capital LLC350,000$2.68M0.7%-15.7%1.961%
5/15/2020Ikarian Capital LLC946,605$7.24M0.5%+345.6%5.304%
5/14/2020Wells Fargo & Company MN37,998$0.29M0.0%-12.3%0.213%
5/14/2020Geode Capital Management LLC191,669$1.47M0.0%+16.9%1.074%
5/14/2020Janus Henderson Group PLC152,307$1.17M0.0%+857.0%0.853%
5/14/2020Wellington Management Group LLP199,315$1.53M0.0%-8.2%1.117%
5/14/2020Alliancebernstein L.P.12,300$94K0.0%+21.8%0.069%
5/14/2020Sphera Funds Management LTD.240,140$1.84M0.2%+62.6%1.346%
5/14/2020Nuveen Asset Management LLC56,672$0.43M0.0%+43.5%0.318%
5/13/2020BNP Paribas Arbitrage SA4,604$35K0.0%+155.6%0.026%
5/13/2020Pictet Asset Management Ltd.631,409$4.83M0.0%+1.5%3.538%
5/13/2020Franklin Resources Inc.233,900$1.79M0.0%-17.5%1.311%
5/12/2020Citigroup Inc.3,887$30K0.0%+53.6%0.022%
5/12/2020Spark Investment Management LLC12,910$98K0.1%N/A0.072%
5/12/2020Victory Capital Management Inc.266,138$2.04M0.0%-3.3%1.491%
5/12/2020JPMorgan Chase & Co.59,365$0.45M0.0%+210.1%0.333%
5/11/2020Ensign Peak Advisors Inc4,253$33K0.0%-50.0%0.024%
5/11/2020State Street Corp245,001$1.87M0.0%+5.6%1.373%
5/11/2020WINTON GROUP Ltd14,604$0.11M0.0%-57.3%0.082%
5/6/2020Alps Advisors Inc.32,390$0.25M0.0%-10.4%0.181%
5/4/2020Victory Capital Management Inc.266,138$2.04M0.0%-3.3%1.491%
5/1/2020BlackRock Inc.872,457$6.67M0.0%+1.4%4.889%
5/1/2020UBS Group AG7,511$57K0.0%-56.8%0.042%
3/11/2020Franklin Resources Inc.283,500$5.05M0.0%N/A1.590%
3/5/2020Nuveen Asset Management LLC39,479$0.70M0.0%+22.6%0.221%
2/20/2020Geode Capital Management LLC163,906$2.92M0.0%+8.0%0.919%
2/18/2020Algert Global LLC13,969$0.25M0.1%-51.4%0.078%
2/18/2020Janus Henderson Group PLC15,915$0.28M0.0%N/A0.089%
2/14/2020Bank of America Corp DE4,360$78K0.0%-43.2%0.024%
2/14/2020Bank of New York Mellon Corp34,999$0.62M0.0%-5.1%0.196%
2/14/2020Goldman Sachs Group Inc.20,213$0.36M0.0%-57.1%0.113%
2/14/2020UBS Group AG17,393$0.31M0.0%+62.4%0.098%
2/14/2020Public Sector Pension Investment Board32,800$0.58M0.0%N/A0.184%
Data available starting January 2016

See Full Table
KalVista Pharmaceuticals logo
KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products include KVD001, a plasma kallikrein inhibitor that completed a Phase II clinical trial for the treatment of DME; KVD900, which is in Phase II clinical trial for treating HAE attacks; and KVD824, an oral plasma kallikrein inhibitor that completed a Phase I clinical trial for treating DME or HAE. The company is headquartered in Cambridge, Massachusetts.
Read More

Today's Range

Now: $30.53
$29.88
$31.38

50 Day Range

MA: $26.01
$14.69
$42.57

52 Week Range

Now: $30.53
$5.61
$45.00

Volume

17,975 shs

Average Volume

1,315,488 shs

Market Capitalization

$547.77 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.13

Who are the company insiders with the largest holdings of KalVista Pharmaceuticals?

KalVista Pharmaceuticals' top insider investors include:
  1. Thomas Andrew Crockett (CEO)
  2. Edward P Feener (Insider)
  3. Benjamin L Palleiko (CFO)
  4. Christopher Yea (Insider)
  5. Andreas Maetzel (Insider)
  6. Daniel B Soland (Director)
  7. Albert Cha (Director)
  8. Life Sciences Fund Iv (Gp) Sv (Major Shareholder)
  9. Svlsf Iv, Llc (Major Shareholder)
  10. Venrock Healthcare Capital Par (Major Shareholder)

Who are the major institutional investors of KalVista Pharmaceuticals?

KalVista Pharmaceuticals' top institutional shareholders include:
  1. BlackRock Inc. — 6.21%
  2. Northern Trust Corp — 1.28%
  3. Dimensional Fund Advisors LP — 1.15%
  4. Dimensional Fund Advisors LP — 1.15%
  5. Ghost Tree Capital LLC — 1.11%
  6. Janus Henderson Group PLC — 0.89%

Which institutional investors are selling KalVista Pharmaceuticals stock?

In the last quarter, KALV stock was sold by these institutional investors:
  1. Ghost Tree Capital LLC
  2. Russell Investments Group Ltd.
  3. Nuveen Asset Management LLC
  4. Samsara BioCapital LLC
  5. Wells Fargo & Company MN
  6. Northern Trust Corp
  7. Janus Henderson Group PLC
  8. GSA Capital Partners LLP
Within the previous year, company insiders that have sold KalVista Pharmaceuticals company stock include:
  1. Thomas Andrew Crockett (CEO)
  2. Edward P Feener (Insider)
  3. Benjamin L Palleiko (CFO)

Which institutional investors are buying KalVista Pharmaceuticals stock?

During the previous quarter, KALV stock was purchased by institutional investors including:
  1. BlackRock Inc.
  2. Renaissance Technologies LLC
  3. Asymmetry Capital Management L.P.
  4. Koshinski Asset Management Inc.
  5. Koshinski Asset Management Inc.
  6. State of Wisconsin Investment Board
  7. JPMorgan Chase & Co.
  8. Dimensional Fund Advisors LP
During the previous year, these company insiders have bought KalVista Pharmaceuticals stock:
  1. Thomas Andrew Crockett (CEO)
  2. Edward P Feener (Insider)
Meet the Hottest Company in the Plant Based Sector!
This rising plant-based foods company has scored 300% in gains after its IPO last year already and is aiming to become a leader in the boom. Learn about it now while it's at the ground-floor!
Continue Reading
pixel